Physician profile
Katie Joshi
NPI 1417144890
$5,617.45
in general payments reported to CMS, 2019-2025
19 companies · $1,446 in 2025
The $1,446 reported for 2025 was more than what 86% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $621 · 2022: $1,102 · 2023: $1,111 · 2024: $1,337 · 2025: $1,446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,794 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,794.00 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,364.59 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $762.98 | 2021-2025 | |
| Genzyme Corporation | $630.71 | 2021-2024 | |
| Janssen Biotech, INC. | $567.42 | 2023-2025 | Tremfya |
| Incyte Corporation | $436.71 | 2021-2025 | Opzelura |
| Amgen INC. | $403.67 | 2022-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $354.26 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $279.04 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Pfizer INC. | $151.47 | 2023-2024 | |
| Ucb, INC. | $119.50 | 2023-2025 | Bimzelx |
| Leo Pharma INC. | $118.35 | 2022-2025 | Anzupgo, Adbry |
| Sun Pharmaceutical Industries INC. | $98.85 | 2021-2025 | Ilumya |
| Galderma Laboratories, L.P. | $71.99 | 2022-2024 | |
| Helsinn Therapeutics (U.S.), INC. | $71.23 | 2022 | |
| Organon LLC | $47.57 | 2024-2025 | Vtama |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $45.04 | 2023-2025 | Zoryve |
| Biofrontera INC. | $41.01 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $39.69 | 2024 | Libtayo |
| Fresenius Kabi USA, LLC | $13.37 | 2024 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Joshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.